HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells.

Abstract
Inhibition of ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, by the irreversible inhibitor alpha-difluoromethylornithine (DFMO) has been shown to decrease the invasiveness of metastatic human breast cancer cell lines. However, the mechanism by which DFMO acts to reduce invasiveness is unclear. Using the human breast cancer cell line MDA-MB-435, the effect of DFMO on metalloprotease gene expression was investigated. DFMO treatment decreases the expression of the metalloprotease meprin alpha, while concurrent treatment with DFMO and the polyamine putrescine partially restored meprin alpha expression levels. Expression of MMP-7 mRNA was reduced by DFMO, while MMPs-1, -2, -3, -14, and meprin beta were unaffected. Treatment of cells with a second inhibitor of polyamine biosynthesis, the S-adenosylmethionine decarboxylase (SAMDC) inhibitor SAM486A, also resulted in a dosage dependent decrease in meprin alpha and MMP-7 mRNA. In addition, DFMO treatment decreased meprin alpha at the protein level by 2 days of treatment, and MMP-7 protein levels at 4 and 6 days. Previous studies have shown that DFMO treatment increases ERK phosphorylation and signaling through the MAP kinase pathway. The decrease in meprin alpha expression was reversed with the MEK inhibitor PD98059, demonstrating that MAP kinase signaling mediates the effect of DFMO and SAM486A. MDA-MB-435 cells treated with the meprin alpha inhibitor actinonin (5 nM) were less invasive in vitro, indicating that meprin alpha is mechanistically involved in invasion. The decrease in meprin alpha expression in DFMO and SAM486A-treated cells indicates a means by which these compounds can decrease the invasiveness of metastatic breast cancer cells.
AuthorsGail L Matters, Andrea Manni, Judith S Bond
JournalClinical & experimental metastasis (Clin Exp Metastasis) Vol. 22 Issue 4 Pg. 331-9 ( 2005) ISSN: 0262-0898 [Print] Netherlands
PMID16170669 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Amidines
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Flavonoids
  • Hydroxamic Acids
  • Indans
  • Ornithine Decarboxylase Inhibitors
  • Polyamines
  • RNA, Messenger
  • 4-amidinoindan-1-one 2'-amidinohydrazone
  • Extracellular Signal-Regulated MAP Kinases
  • Mitogen-Activated Protein Kinase Kinases
  • Metalloendopeptidases
  • meprin A
  • Matrix Metalloproteinase 7
  • actinonin
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Eflornithine
Topics
  • Amidines (pharmacology)
  • Antineoplastic Agents (pharmacology)
  • Breast Neoplasms (enzymology, pathology)
  • Down-Regulation
  • Eflornithine (pharmacology)
  • Enzyme Inhibitors (pharmacology)
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Flavonoids (pharmacology)
  • Gene Expression (drug effects)
  • Humans
  • Hydroxamic Acids (pharmacology)
  • Indans (pharmacology)
  • Matrix Metalloproteinase 7 (genetics, metabolism)
  • Metalloendopeptidases (antagonists & inhibitors, genetics, metabolism)
  • Mitogen-Activated Protein Kinase Kinases (antagonists & inhibitors)
  • Neoplasm Invasiveness
  • Ornithine Decarboxylase Inhibitors
  • Phosphorylation (drug effects)
  • Polyamines (metabolism)
  • RNA, Messenger (analysis, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: